I think the report is good - nearly half the MC in cash backing, 10 private payer meetings coming, record patient tests, 34% ave licence fee increase across the renewed 38 units.
Also they keep winning against private payors - in the end cheaper for the payors not to have to review endless numbers of cases, and cheaper for IPD too, and better for patients. This does not look like a business that will fail to gain reimbursement. However that will be the next catalyst.
Ann: Appendix 4C & Quarterly Activities Report - Jun-2022 Qtr, page-4
Add IPD (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.3¢ |
Change
0.004(5.80%) |
Mkt cap ! $147.6M | |||
| Open | High | Low | Value | Volume |
| 6.9¢ | 7.3¢ | 6.8¢ | $50.00K | 698.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 7.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.3¢ | 176847 | 1 |
View Market Depth
| Last trade - 16.10pm 17/06/2024 (20 minute delay) ? |
|
|||||
|
Last
7.2¢ |
Change
0.004 ( 7.30 %) |
||||
| Open | High | Low | Volume | ||
| 6.8¢ | 7.2¢ | 6.8¢ | 334775 | ||
| Last updated 15.51pm 17/06/2024 ? | |||||
| IPD (ASX) Chart |
